Aventus Thrombectomy System Pulmonary Embolism Clinical Study

Exclusion Criteria

• •1. Prior PE ≤ 180 days from index procedure
• •2. Current hospitalization for other condition(s)
• •3. Thrombolytic use ≤ 14 days of baseline CTA
• •4. Pulmonary hypertension with peak pulmonary artery systolic pressure \> 70 mmHg by right heart catheterization
• •5. FiO2 requirement \> 40% or \> 6 LPM to keep oxygen saturation \> 90%
• •6. Hematocrit \< 28% within 6 hours of index procedure
• •7. Platelets \< 100,000/μL
• •8. Serum creatinine \> 1.8 mg/dL
• •9. International normalized ratio (INR) \> 3
• •10. Presence of intracardiac lead in the right ventricle or right atrium placed \< 180 days prior to index procedure
• •11. Cardiovascular or pulmonary surgery ≤ 7 days prior to index procedure
• •12. Actively progressing cancer treated by chemotherapeutics
• •13. Known bleeding diathesis or coagulation disorder
• •14. Left bundle branch block
• •15. History of severe or chronic pulmonary arterial hypertension
• •16. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
• •17. History of uncompensated heart failure
• •18. History of underlying lung disease that is oxygen dependent
• •19. History of chest irradiation
• •20. History of heparin-induced thrombocytopenia (HIT)
• •21. Any contraindication to systemic or therapeutic doses of heparin or anticoagulants
• •22. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
• •23. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for aspiration thrombectomy intervention such as the inability to navigate to target location, predominantly chronic clot or non-clot embolus
• •24. Life expectancy of \< 90 days, as determined by Investigator
• •25. Female who is pregnant or nursing
• •26. Current participation in another investigational drug or device treatment study that has not reached the primary endpoint or the Investigator feels would impact their ability to participate in this clinical trial
• •27. Subject has known residual Iliac Deep Vein Thrombosis (DVT), Inferior Vena Cava (IVC) clot or clot in transit (right atrium and/or right ventricular)
• •28. Subject on extracorporeal membrane oxygenation (ECMO)